Dhr. van Dekken

E-mailadresh.vandekken@gmail.com

Biografie 1. Pinkel D, Gray JW, Trask B, van den Engh G, Fuscoe J, van Dekken H. Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harbor Symposia on Quantitative Biology LI:151 157, 1986.
2. Arkesteijn GJA, van Dekken H, Hagenbeek A. Dual laser beam flow karyotyping in acute leukemia: Preclinical studies in a rat model. In: Chromosomes in Hematology ((R Becher, AA Sandberg, CG Schmidt, Eds.), pp. 144-145, 1986.
3. Van Dekken H, Pinkel D, Mullikin J, Gray JW. Enzymatic production of single stranded DNA as a target for fluorescence in situ hybridization. Chromosoma (Berlin) 97:1 5, 1988.
4. Van Dekken H, Bauman JGJ. A new application of in situ hybridization: Detection of numerical and structural chromosome aberrations with a combination centromeric telomeric DNA probe. Cytogenet Cell Genet 48:188 189, 1988.
5. Trask B, van den Engh G, Pinkel D, Mullikin J, Waldman F, van Dekken H, Gray J. Fluorescence in situ hybridization to interphase cell nuclei in suspension allows flow cytometric analysis of chromosome content and microscopic analysis of nuclear organization. Hum Genet 78:251 259, 1988.
6. Nooter K, Oostrum R, Jonker RR, van Dekken H, Stokdijk W, van den Engh GJ. Effect of cyclosporin A on daunorubicin accumulation in multidrug resistant P388 leukemia cells measured by real time flow cytometry. Cancer Chemother. Pharmacol. 23:296 300, 1989.
7. Van Dekken H, Hagenbeek A, Bauman JGJ. Detection of host cells following sex mismatched bone marrow transplantation by fluorescent in situ hybridization with a Y chromosome specific probe. Leukemia 3:724 728, 1989.
8. Van Dekken H, Pinkel D, Mullikin J, Trask B, van den Engh G, Gray J. Three dimensional analysis of the organization of human chromosome domains in human and human hamster hybrid interphase nuclei. J Cell Sci 94:299 306, 1989.
9. Gray JW, Pinkel D, Trask B, van den Engh G, Pallavicini M, Fuscoe J, Mullikin J, van Dekken H. Analytical cytology applied to detection of prognostically important cytogenetic aberrations: Current status and future directions. In: Prediction of tumor treatment response (JD Chapman, LJ Peters, HR Whithers, Eds.), pp. 111 126. Pergamon Press, New York, 1989.
10. Van Dekken H, Pinkel D, Mullikin J, Trask B, van den Engh G, Gray J. Three dimensional reconstruction of human chromosomes in hybrid and human cell line nuclei using fluorescence in situ hybridization. Acta Histochemica, Suppl XXXVII:91 94, 1989.
11. Bauman JGJ, van Dekken H. Flow cytometry of fluorescent in situ hybridization to detect specific RNA and DNA sequences. Acta Histochemica, Suppl XXXVII:65-69, 1989.
12. Van Dekken H, Arkesteijn GJA, Visser JWM, Bauman JGJ. Flow cytometric quantification of human chromosome specific repetitive DNA sequences by single and bicolor fluorescent in situ hybridization to lymphocyte interphase nuclei. Cytometry (Special Issue Analytical Cytogenetics) 11:153 164, 1990.
13. Arkesteijn GJA, van Dekken H, Martens ACM, Hagenbeek A. Clinical applications of flow karyotyping in myelocytic leukemia by stimulation of different subpopulations of cells in blood or bone marrow samples. Cytometry (Special Issue Analytical Cytogenetics) 11:196 201, 1990.
14. Van Dekken H, van Rotterdam A, Jonker R, van der Voort HTM, Brakenhoff GJ, Bauman JGJ. Confocal microscopy as a tool for the study of the intranuclear topography of chromosomes. J Microsc 158:207-214, 1990.
15. Bauman JGJ, Bayer JA, van Dekken H. Fluorescent in situ hybridization to detect cellular RNA's by flow cytometry and confocal microscopy. J Microsc 157:73 81, 1990.
16. Van Dekken H, van Rotterdam A, Jonker RR, van der Voort HTM, Brakenhoff GJ, Bauman JGJ. Spatial topography of a pericentromeric region (1q12) in lymphoid and myeloid hemopoietic cells studied by in situ hybridization and confocal microscopy. Cytometry 11:570-578, 1990.
17. Van Dekken H, van der Voort HTM, Brakenhoff GJ, Bauman JGJ. Three dimensional reconstruction of pericentromeric (1q12) DNA and ribosomal RNA sequences in HL60 cells after double target in situ hybridization and confocal microscopy. Cytometry 11:579-585, 1990.
18. Van Dekken H, Pizzolo JG, Kelsen DP, Melamed MR. Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome specific DNA probes. Cancer 66:491-497, 1990.
19. Van Dekken H, Pizzolo JG, Reuter VE, Melamed MR. Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome specific DNA probes. Cytogenet Cell Genet 54:103-107, 1990.
20. Van Dekken H, Schervish E, Pizzolo JG, Fair WR, Melamed MR. Simultaneous detection of fluorescent in situ hybridization and in vivo incorporated BrdU in a human bladder tumor. J Pathol 164:17-22, 1991.
21. Van Dekken H, Kerstens HMJ, Tersteeg TA, Verhofstad AAJ, Vooijs GP. Histological preservation after in situ hybridization to archival solid tumor sections allows discrimination of cells bearing numerical chromosome changes. J Pathol 168:317-324, 1992.
22. Kerstens HMJ, van Dekken H. In situ hybridisatie en morfologie behoud. Histotechniek 11:106-110, 1992.
23. Cleutjens CBJM, van Eekelen CCEM, van Dekken H, Smit EME, Hagemeijer A, Wagner MJ, Wells HG, Trapman J. The human C/EBP (CRP3/CELF) gene: Structure and chromosomal localization. Genomics 16:520-523, 1993.
24. Van Dekken H, Hulspas R. Review article: Spatial analysis of intranuclear human repetitive DNA regions by in situ hybridization and digital fluorescence microscopy. Histochem J 25:173-182, 1993.
25. Van Dekken H, Alers JC. Letter to the editor: Loss of chromosome Y in prostatic cancer cells, but not in stromal tissue. Cancer Genet Cytogenet 66:131-132, 1993.
26. Van Dekken H, Brakenhoff GJ, Bauman JGJ. DNA in situ hybridization and confocal microscopy. In: Hybridization techniques for electron microscopy (G Morel, Ed.), pp. 65-97. CRC Press, Inc., Boca Raton, 1993.
27. Van Dekken H, Bosman FT, Teijgeman R, Vissers CJ, Tersteeg TA, Kerstens HMJ, Vooijs GP, Verhofstad AAJ. Identification of numerical chromosome aberrations in archival tumors by in situ hybridization to routine paraffin sections: Analysis of 23 phaeochromocytomas. J Pathol 171:161-171, 1993.
28. Krishnadath KK, Tilanus HW, Alers JC, Mulder AH, van Dekken H. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Cytometry 15:176-184, 1994.
29. El-Naggar AK, van Dekken H, Ensign LG, Pathak S. Interphase cytogenetics in paraffin-embedded sections from renal cortical neoplasms: Correlations with cytogenetic and flow cytometric DNA analyses. Cancer Genet Cytogenet 73:134-141, 1994.
30. Debruyne FMJ, Collins VP, van Dekken H, Jenkins RB, Klocker R, Schalken JA, Sesterhenn IA. Cytogenetics of prostate cancer. In: Diagnosis and prognostic parameters in localized prostate cancer (L Andersson, Ed.). Scand J Urol Nephrol Suppl 162:65-71, 1994.
31. Robben H, van Dekken H, Poddighe PJ, Vooijs GP. Identification of aberrant cells in cytological specimens by combined in situ hybridization and immunocytochemistry. Cytopathology 5:384-391, 1994.
32. Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast ThH, van Dekken H. Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: Analysis of 25 radical prostatectomies and 17 adjacent intraepithelial neoplasias (PIN). Genes Chromosomes Cancer 12:241-250, 1995.
33. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WCJ, Teijgeman R, Mulder AH, Bosman FT, van Dekken H. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 55:1971-1976, 1995.
34. Van Dekken H, Krijtenburg PJ. Automation of cancer interphase cytogenetics. Microscopy & Analysis, March Vol:13-14, 1995.
35. Pahlplatz MM, de Wilde PCM, Poddighe P, van Dekken H, Vooijs GP, Hanselaar AGJM. A model for evaluation of in situ hybridization spot-count distributions in tissue sections. Cytometry 20:193-202, 1995.
36. Alers JC, Krijtenburg PJ, Vissers CJ, Bosman FT, van der Kwast ThH, van Dekken H. Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancers. Cytometry 21:84-94, 1995.
37. Alers JC, Krijtenburg PJ, Vissers KJ, Krishnadath SK, Bosman FT, van Dekken H. Interphase in situ hybridization to disaggregated and intact tissue specimens of prostatic adenocarcinoma. Histochem Cell Biol 104:479-486, 1995.
38. Alers JC, van Dekken H. Book: Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Progr Histochem Cytochem series vol. 31/3 (pp. 1-137), 1996.
39. Krijtenburg PJ, Alers JC, Bosman FT, van Dekken H. Comparison of automated and manual analysis of interphase in situ hybridization in tissue sections and nuclear suspensions. Cytometry 25:99-103, 1996.
40. Mesker WJ, Alers JC, Sloos WCR, Vrolijk H, Raap AK, van Dekken H, Tanke HJ. Automated assessment of numerical chromosomal aberrations in paraffin embedded prostate tumor cells stained by in situ hybridization. Cytometry (Communications in Clinical Cytometry) 26:298-304, 1996.
41. Van Dekken H, Rosenberg C, Krijtenburg PJ, Alers JC. Review article: Interphase cytogenetics and comparative genomic hybridization of human epithelial cancers and precursor lesions. Histochem Cell Biol (Special Issue) 108:419-430, 1997.
42. Rosso SM, van Dekken H, Krishnadath KK, Alers JC, Kros JM. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 56:1125-1131, 1997.
43. Janssen M, Baggen MGA, van Dekken H, Ouwendijk RJTh. Bilateral adrenal enlargement as a first sign of systemic vasculitis. Neth J Med 51:146-149, 1997.
44. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WCJ, Verkerk AM, Schröder FH, van der Kwast ThH, Bosman FT, van Dekken H. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 77:437-448, 1997.
45. Alers JC, Krijtenburg PJ, Hop WCJ, Bolle WABM, Schröder FH, van der Kwast ThH, Bosman FT, van Dekken H. Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: Tumors that recur in time display an intermediate genetic status between non-persistent and metastatic tumors. J Pathol 185:273-283, 1998.
46. Van Dekken H, Geelen E, Dinjens WNM, Wijnhoven BPL, Tilanus HW, Tanke HJ, Rosenberg C. Comparative genomic hybridization of cancer of the gastro-esophageal junction: Deletion of 14q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 59:748-752, 1999.
47. Van den Boogert J, van Hillegersberg R, van Staveren HJ, de Bruin RW, van Dekken H, Siersema PD, Tilanus HW. Timing of illumination is essential for effective and safe photodynamic therapy: A study in the normal rat oesophagus. Br J Cancer 79:825-830, 1999.
48. Alers JC, Krijtenburg PJ, Vissers KJ, van Dekken H. The effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization: EDTA is highly preferable to a routinely used acid decalcifier. J Histochem Cytochem 47:703-710, 1999.
49. Wijnhoven BPL, Siersema PD, Hop WCJ, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Br J Surg 86:529-535, 1999.
50. Alers JC, Rochat J, Krijtenburg PJ, van Dekken H, Raap AK, Rosenberg C. Universal Linkage System (ULS): An improved method for labeling archival DNA for comparative genomic hybridization. Genes Chromosomes Cancer 25:301-305, 1999.
51. Van Dekken H, Vissers CJ, Tilanus HW, Tanke HJ, Rosenberg C. Clonal analysis of a multifocal oesophageal (Barrett’s) adenocarcinoma by comparative genomic hybridization. J Pathol 188:263-266, 1999.
52. Kros JM, van Run PRWA, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJJ, van Dekken H. Genetic aberrations in oligodendroglial tumors: An analysis using comparative genomic hybridization (CGH). J Pathol 188:282-288, 1999.
53. Wijnhoven BPL, de Both NJ, van Dekken H, Tilanus HW, Dinjens WN. E-cadherin gene mutations are rare in oesophageal adenocarcinomas. Br J Cancer 80:1652-1657, 1999.
54. Van Dekken H, Krijtenburg PJ, Alers JC. DNA in situ hybridization (interphase cytogenetics) versus comparative genomic hybridization (CGH) in human cancer: Detection of numerical and structural chromosome aberrations. Acta Histochem 102:85-94, 2000.
55. Alers JC, Rochat J, Krijtenburg PJ, Hop WCJ, Kranse R, Rosenberg C, Tanke HJ, Schröder FH, van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest 80:931-942, 2000.
56. Kros JM, Waarsenburg N, Hayes DP, Hop WCJ, van Dekken H. Cytogenetic analysis of gemistocytic cells in gliomas. J Neuropathol Exp Neurol 59:679-686, 2000.
57. Hinnen P, de Rooij FWM, Terlouw EM, Edixhoven A, van Dekken H, van Hillegersberg R, Tilanus HW, Wilson JHP, Siersema PD. Porphyrin biosynthesis in human Barrett’s oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid. Br J Cancer 83:539-543, 2000.
58. Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, van Dekken H. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: Analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol 192:207-215, 2000.
59. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WCJ, van der Kwast ThH, Schröder FH, Tanke HJ, van Dekken H. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: Early cancers may contain agressive genetic features. Am J Pathol 158:399-406, 2001.
60. Riegman PHJ, Vissers KJ, Alers JC, Geelen E, Hop WCJ, Tilanus HW, van Dekken H. Genomic alterations in malignant transformation of Barrett’s esophagus. Cancer Res 61:3164-3170, 2001.
61. De Pender AMG, Alers JC, Vissers KJ, de Both NJ, Dinjens WNM, van Dekken H. Evaluation of oncogene amplification in intact and truncated cell nuclei of gastro-esophageal cancer cell lines by DNA in situ hybridisation. Acta Histochem 103:127-138, 2001.
62. Van Dekken H, Alers JC, Riegman PHJ, Rosenberg C, Tilanus HW, Vissers K. Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am J Pathol 158:1961-1967, 2001.
63. Kros JM, van Run PRWA, Alers JC, Avezaat CJJ, Luider ThM, van Dekken H. Spatial variability of genomic aberrations in a large glioblastoma resection specimen. Acta Neuropath 102:103-109, 2001.
64. Vissers KJ, Riegman PHJ, Alers JC, Tilanus HW, van Dekken H. Involvement of cancer-activating genes on chromosomes 7 and 8 in esophageal (Barrett’s) and gastric cardia adenocarcinoma. Anticancer Res 21:3813-3820, 2001.
65. Van Dekken H. Histopathology of Barrett’s esophagus. In: Barrett’s Esophagus (HW Tilanus & SEA Attwood, Eds.), pp. 159-167. Kluwer Academic Publishers, Dordrecht, 2001.
66. Riegman PHJ, Burgart LJ, Wang KK, Wink-Godschalk JCJ, Dinjens WNM, Siersema PD, Tilanus HW, van Dekken H. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett’s esophagus. Cancer Res 62:1531-1533, 2002.
67. Rosenberg C, Geelen E, IJszenga MJ, Pearson P, Tanke HJ, Dinjens WNM, van Dekken H. Spectrum of genetic changes in gastro-esophageal cancer cell lines determined by an integrated molecular cytogenetic approach. Cancer Genet Cytogenet 135:35-41, 2002.
68. Gudlaugsdottir S, van Dekken H, Stijnen T, Wilson JHP. Prolonged use of proton pump inhibitors, CagA status and the outcome of Helicobacter pylori gastritis. J Clin Gastroenterol 34:536-540, 2002.
69. Keller JJ, Westerman AM, de Rooij FWM, Wilson JHP, van Dekken H, Giardiello FM, Weterman MA, Offerhaus GJA. Molecular genetic evidence of an association between nasal polyposis and the Peutz-Jeghers syndrome. Ann Intern Med 136:854-855, 2002.
70. Hinnen P, de Rooij FWM, Hop WCJ, Edixhoven A, van Dekken H, Wilson JHP, Siersema PD. Timing of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of patients with Barrett’s esophagus. J Photochem Photobiol B: Biol 68:8-14, 2002.
71. Siersema PD, Hage M, Van Der Gaast A, Van Dekken H, Kok TC, Tilanus HW, Kuipers EJ. Cure of Barrett's carcinoma by ifosfamide chemotherapy. Eur J Gastroenterol Hepatol 14:1261-1264, 2002.
72. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662-1669, 2002.
73. West RL, van de Vrie W, Schouten WR, van Dekken H, Kuipers EJ. De maligne kant van inflammatoir darmlijden. Ned Tijdschr Geneesk 146:2521-2524, 2002.
74. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schröder FH, Vissers KJ, Watson VJE, Wildhagen MF Collins C, van Dekken H. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol 162:763-770, 2003.
75. Van Dekken H, Wink J, Alers JC, IJzermans JN, de Man RA, Zondervan PE. Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: A detailed analysis of two cases and a review of the literature. Acta Histochem 105:29-41, 2003.
76. Looijenga LHJ, Stoop H, de Leeuw HPJC, de Goveia Brazao CA, Gillis AJM, van Roozendaal KEP, van Zoelen EJJ, Weber RFA, van Dekken H, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW. Identification of cells with pluripotent potential in human germ cell tumors by POU5F1 (OCT3/4). Cancer Res 63:2244-2250, 2003.
77. Van Dekken H, Alers JC, Damen IAAJ, Vissers KJ, Krijtenburg PJ, Hoedemaeker RF, Wildhagen MF, Hop WCJ, van der Kwast ThH, Tanke HJ, Schröder FH. Genetic evaluation of localized prostate cancer in a cohort of 40 patients: Gain of distal 8q discriminates between progressors and non-progressors. Lab Invest 83:789-796, 2003.
78. Hage M, Van Dekken H, Siersema PD. Letter to the editor: Cure of Barrett's carcinoma by ifosfamide chemotherapy. Eur J Gastroenterol Hepatol 15:829, 2003.
79. De Leng W, Westerman AM, Weterman MAJ, van Dekken H, de Rooij FWM, Wilson JHP, Gruber S, de Goeij AFPM, Giardello FM, Offerhaus GJA, Keller JJ. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 9:3065-3072, 2003.
80. Offerhaus GJA, Correa P, van Eeden S, Geboes K, Drillenburg P, Vieth M, van Velthuysen ML, Watanabe H, Sipponen P, ten Kate FJW, Bosman FT, Bosma A, Ristimaki A, van Dekken H, Riddell R, Tytgat GNJ. Report of an Amsterdam working group on Barrett esophagus. Virchows Arch 443:602-608, 2003.
81. Van Dekken H, Paris PL, Albertson DG, Alers JC, Andaya A, Kowbel D, van der Kwast TH, Pinkel D, Schröder FH, Vissers KJ, Wildhagen MF, Collins C. Evaluation of genetic patterns in different tumor areas of intermediate grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39:249-256, 2004.
82. Watson JEV, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, van Dekken H, Ginzinger D, Haqq C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK, Paris PL, Collins C. Integration of high resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23:3487-3494, 2004.
83. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, Grool TE, van Veen RLP, Sterenborg HCJM, Kuipers EJ. 5-Aminolevulinic acid photodynamic therapy versus Argon plasma coagulation for ablation of Barrett’s oesophagus: A randomized trial. Gut 53:785-790, 2004.
84. Koppert LB, Wijnhoven BPL, Tilanus HW, van Dekken H, Dinjens WNM. Immunohistochemical analysis and prognostic significance of neuroendocrine cells in Barrett’s mucosa and adenocarcinomas of the gastro-esophageal junction. Int J Surg Path 12:117-125, 2004.
85. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JEV, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast ThH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13:1303-1313, 2004.
86. Moons LMG, Bax DA, Kuipers EJ, van Dekken H, Haringsma J, van Vliet AHM, Siersema PD, Kusters JG. The homeodomain protein CDX2 is an early marker of Barrett’s oesophagus. J Clin Pathol 57:1063-1068, 2004.
87. Bax DA, Haringsma J, Einerhand AWC, van Dekken H, Blok P, Siersema PD, Kuipers EJ, Kusters JG. MUC4 is increased in high-grade intraepithelial neoplasia in Barrett's esophagus and is associated with a pro-apoptotic bax/bcl2 ratio. J Clin Pathol 57:1267-1272, 2004.
88. Hage M, Siersema PD, van Dekken H, Steyerberg E, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett’s oesophagus after a mean follow-up of 12.7 years. Scan J Gastroenterol 39:1175-1179, 2004.
89. Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Molecular evaluation of ablative therapy of Barrett’s esophagus. J Pathol 205:57-64, 2005.
90. Van Duin M, van Marion R, Watson JEV, Paris PL, Lapuk A, Brown N, Oseroff VV, Albertson DG, Pinkel D, de Jong P, Nacheva EP, Dinjens W, van Dekken H, Collins C. Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry Part A 63A:10-19, 2005.
91. Vissers KJ, Dinjens WNM, Riegman PHJ, Tilanus HW, van Dekken H. Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett’s) adenocarcinoma. Anticancer Res 25:913-916, 2005.
92. Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJW, Bergman JJHGM, Siersema PD, van Dekken H, van Lanschot JJB. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 446:497-504, 2005.
93. Van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PLM, van Dekken H. Expression of apoptosis-related proteins during malignant progression in chronic ulcerative colitis. J Clin Pathol 58:811-814, 2005.
94. Van Dekken H, Verhoef C, Wink J, van Marion R, Vissers KJ, Hop WCJ, de Man RA, Ijzermans JN, van Eijck CHJ, Zondervan PE. Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis. Acta Histochem 107:161-171, 2005.
95. Moons LMG, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WHM, Kwekkeboom J, van Vliet AHM, Siersema PD. Barrett’s oesophagus is characterised by a predominant humoral inflammatory response. J Pathol 207:269-276, 2005.
96. Van Duin M, van Marion R, Vissers K, Watson JEV, van Weerden WM, Schröder FH, Hop WCJ, van der Kwast TH, Collins C, van Dekken H. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:438-449, 2005.
97. Smeenk HG, Incrocci L, Kazemier G, van Dekken H, Tran KT, Jeekel J, van Eijck CH. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg 22:321-328, 2005.
98. Koppert LB, Wijnhoven BPL, van Dekken H, Tilanus HW, Dinjens WNM. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92:169–190, 2005.
99. Hage M, Siersema PD, Vissers KJ, Dinjens WNM, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Genomic analysis of Barrett’s esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci. Int J Cancer 118:155-160, 2006.
100. Lin L, Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG. Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer 45:319–331, 2006.
101. Wolters LMM, Hermans JJ, van Dekken H, Kazemier G, Schouten WR, Kuipers EJ. Incidentele cysteuze structuren in de bovenbuik: verwijderen of niet? Ned Tijdschr Geneesk 150:169-174, 2006.
102. Hage M, Siersema PD, van Dekken H. Review article: Oesophageal pathology following ablation of Barrett’s mucosa. Curr Diagn Pathol 12:127-135, 2006.
103. Van Dekken H, Wink JC, Vissers KJ, van Marion R, Koppert LB, Tilanus HW, Siersema PD, Tanke HJ, Szuhai K, Hop WCJ. Genomic analysis of early adenocarcinoma of the esophagus or gastro-esophageal junction: Tumor progression is associated with alteration of 1q and 8p sequences. Genes Chromosomes Cancer 45:516-525, 2006.
104. Leeuwenburgh I, van Dekken H, Scholten P, Hansen BE, Haringsma J, Siersema PD, Kuipers EJ. Esophagitis is common in patients with achalasia after pneumodilatation. Aliment Pharmacol Ther 23:1197-1203, 2006.
105. Postma R, van Marion R, van Duin M, Vissers KJ, Wink JC, Schröder FH, Tanke HJ, Szuhai K, van der Kwast ThH, van Dekken H. Array-based genomic analysis of screen detected Gleason score 6 and 7 prostatic adenocarcinomas. Anticancer Res 26:1193-1200, 2006.
106. Van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, Rosenberg C, IJszenga M, Szuhai K. Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 166:157-162, 2006.
107. Dinjens WNM, Koppert LB, Dezentje DA, Abbou M, van Ballegooijen ES, Sleddens HFBM, van Dekken H, Tilanus HW, Wijnhoven BPL. Identification of a 7.1–mega base pairs minimal deletion at 14q31.1-32.11 in adenocarcinomas of the gastroesophageal junction. Hum Pathol 37:534-541, 2006.
108. Van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WMH, van Dekken H, Tran TCK, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 94:1389-1394, 2006.
109. Leeuwenburgh I, Haringsma J, Van Dekken H, Scholten P, Siersema PD, Kuipers EJ. Long-term risk of oesophagitis, Barrett's oesophagus and oesophageal cancer in achalasia patients. Scand J Gastroenterol Suppl 243:7-10, 2006.
110. De Jonge PJF, Kuipers EJ, Honkoop P, Wolters LMM, van Dekken H, Steyerberg EW, Siersema PD. Risk factors for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 101:1421-1429, 2006.
111. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor–negative prostate cancer. Cancer Res 66:10658-10663, 2006.
112. Van Dieren JM, Wink JC, Vissers KJ, van Marion R, Hoogmans MMCP, Dinjens WNM, Schouten WR, Tanke HJ, Szuhai K, Kuipers EJ, van der Woude CJ, van Dekken H. Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol 15:216-222, 2006.
113. Van Dekken H, Wink JC, Vissers KJ, van Marion R, Franken PF, Hoogmans MMCP, Dinjens WNM, Schouten WR, Kuipers EJ, van der Woude CJ. Genomic analysis of a case of multifocal adenocarcinoma in ulcerative colitis. Virchows Arch 449:716-721, 2006.
114. Kerkhof M, Bax DA, Moons LMG, van Vuuren AJ, van Dekken H, Kuipers EJ, Kusters JG, Siersema PD. Does CDX2 expression predict Barrett’s metaplasia in oesophageal columnar epithelium without goblet cells? Aliment Pharmacol Ther 24:1613-1621, 2006.
115. Post PN, Siersema PD, van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands; a nation-wide registry of pathology reports. Scan J Gastroenterol 42:17-22, 2007.
116. Hameetman L, Szuhai K, Yavas A, Knijnenburg J, van Duin M, van Dekken H, Taminiau AHM, Cleton-Jansen AM, Bovee JVMG, Hogendoorn PCW. The role of EXT1 in nonhereditary osteochondroma: Identification of homozygous deletions. J Natl Cancer Inst 99:396-406, 2007.
117. Bax D, Siersema PD, Moons LM, van Dekken H, Tilanus HW, Kusters JG, Kuipers EJ. CDX2 expression in columnar metaplasia of the remnant esophagus in patients who underwent esophagectomy. J Clin Gastroenterol 41:375-379, 2007.
118. De Leng WW, Westerman AM, Weterman M, Jansen M, van Dekken H, Giardiello FM, de Rooij FW, Wilson P, Offerhaus GJ, Keller JJ. Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathologic and molecular genetic entity. J Clin Pathol 60:392-396, 2007.
119. Smeenk HG, Erdmann J, van Dekken H, van Marion R, Hop WC, Jeekel J, van Eijck CH. Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig Surg 24:38-45, 2007.
120. Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50:920-927, 2007.
121. Van Dekken H, Wink JC, Vissers KJ, Franken PF, Schouten WR, Hop WCJ, Kuipers EJ, Fodde R, van der Woude CJ. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem 109:266-272, 2007.
122. Bax DA, Siersema PD, Haringsma J, Kuipers EJ, Vos AJ, van Dekken H, van Vliet AH, Kusters JG. High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B. Scand J Gastroenterol 42:902-910, 2007.
123. Memari N, Diamandis EP, Earle T, Campbell A, van Dekken H, van der Kwast ThH. Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues. Prostate 67:1465-1474, 2007.
124. Boonstra JJ, van der Velden AW, Beerens ECW, van Marion R, Morito-Fujimura Y, Nishihira T, Tselepis C, Hainaut P, Lowe AW, Beverloo B, van Dekken H, Tilanus HW, Dinjens WNM. Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res 67:7996-8001, 2007.
125. Smeenk HG, van Eijck CHJ, Hop WCJ, Erdmann J, Tran TCK, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246:734-740, 2007.
126. Van Duin M, van Marion R, Vissers KJ, Hop WCJ, Dinjens WNM, Tilanus HW, Siersema PD, van Dekken H. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res 118:130–137, 2007.
127. Omloo JMT, Lagarde SM, Hulscher JBF, Reitsma JB, Fockens P, van Dekken H, ten Kate FJW, Obertop H, Tilanus HW, van Lanschot JJB. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five year survival of a randomized clinical trial. Ann Surg 246:992-1001, 2007.
128. De Jonge PJF, Wolters LMM, Steyerberg EW, van Dekken H, Kusters JG, Kuipers EJ, Siersema PD. Environmental risk factors in the development of adenocarcinoma of the esophagus or gastric cardia: a cross-sectional study in a Dutch cohort. Aliment Pharmacol Ther 26:31-9, 2007.
129. Kerkhof M, Kusters JG, van Dekken H, Kuipers EJ, Siersema PD. Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. Cell Oncol 29:507-17, 2007.
130. Van der Woude CJ, van Dekken H, Kuipers EJ. Bleeding: relapse of long-standing colitis? Endoscopy 39:E121-E122, 2007.
131. Verhoef C, van Dekken H, Hofland LJ, Zondervan PE, de Wilt JHW, van Marion R, de Man RA, IJzermans JNM, van Eijck CHJ. Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumour characteristics. Dig Surg 25:21-26, 2008.
132. Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark 4:1-10, 2008.
133. De Jonge PJ, Siersema PD, van Breda SG, van Zoest KP, Bac DJ, Leeuwenburgh I, Ouwendijk RJ, van Dekken H, Kusters JG, Kuipers EJ. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Aliment Pharmacol Ther 28:127-136, 2008.
134. Van Dekken H, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Wink JC, van Duin M. Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer 47:649-656, 2008.
135. Ramsoekh D, van Leerdam ME, Dekker E, Ouwendijk RT, van Dekken H, Kuipers EJ. Sporadic duodenal adenoma and the association with colorectal neoplasia: a case-control study. Am J Gastroenterol 103:1505-1509, 2008.
136. Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, Kusters JG. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol 103:1510-1516, 2008.
137. Baars JE, Kuipers EJ, van Dekken H, van der Woude. Surgery is indicated for persistent enterocutaneous fistulizing Crohn’s disease. Clinical Medicine: Gastroenterology 1:1–3, 2008.
138. Dost D, van Leerdam ME, van Dekken H, Weimar W, Kuipers EJ, Bijl AH, van Gelder T. M. Crohn-like enterocolitis associated with mycophenolic acid treatment. Gut 57:1330, 2008.
139. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF, Boormans JL, van der Kwast TH, van Dekken H, Bangma CH, Korsten H, Kraaij R, Jenster G, Trapman J. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68:7541-7549, 2008.
140. Tran TC, van 't Hof G, Kazemier G, Hop WC, Pek C, van Toorenenbergen AW, van Dekken H, van Eijck CH. Pancreatic fibrosis correlates with exocrine pancreatic insufficiency after pancreatoduodenectomy. Dig Surg 25:311-318, 2008.
141. Van Dekken H, Hop WCJ, Tilanus HW, Haringsma J, van der Valk H, Wink JC, Vissers KJ. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett’s esophagus. Am J Clin Pathol 130:745-753, 2008.
142. Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, Hop WC, Kazemier G, van Eijck CH. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 248:1031-1041, 2008.
143. Van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch O, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surgery 8:21, 2008.
144. Van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, Nieuwenhuis EE, van der Woude CJ. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 15:193-198, 2009.
145. Van Dekken H, Tilanus HW, Hop WCJ, Dinjens WNM, Wink JC, Vissers KJ, van Marion R. Array CGH, expression array and protein analysis of critical regions on chromosome 1q, 7q and 8p in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 189:37-42, 2009.
146. Van Meerten E, van der Gaast A, Tilanus HW, Poley JW, Muller K, van Dekken H. Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: the Rotterdam experience. J Surg Oncol 100:32-37, 2009.
147. De Vries AC, Haringsma J, de Vries R, ter Borg F, Nagtzaam N, van Dekken H, Steyerberg EW, Kuipers EJ. The use of clinical, histological, and serological parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endoscopy 70:18-25, 2009.
148. Grotenhuis BA, Wijnhoven BPL, van Marion R, van Dekken H, Hop WC, Tilanus HW, van Lanschot JJB, van Eijck CHJ. The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 138:608-612, 2009.
149. Boonstra JJ, Koppert LB, Wijnhoven BP, Tilanus HW, van Dekken H, Tran TCK, van der Gaast A. Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. J Surg Oncol 100:407-413, 2009.
150. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol 104:2673-2680, 2009.
151. Capelle LG, de Vries AC, Haringsma J, Steyerberg EW, Looman CW, Nagtzaam NM, van Dekken H, ter Borg F, de Vries RA, Kuipers EJ. Serum levels of leptin as marker for patients at high risk of gastric cancer. Helicobacter 14:596-604, 2009.
152. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JCIY, van der Togt ACM, Habbema DJF, Kuipers EJ. Screening for colorectal cancer; randomised trial comparing guiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59:62-68, 2010.
153. Boonstra J, van Marion R, Beer D, Lin L, Chaves P, Ribeiro C, Pereira A, Roque L, Darnton S, Altorki N, Schrump D, Klimstra D, Tang L, Eshleman J, Alvarez H, Shimada Y, van Dekken H, Tilanus H, Dinjens W. Contaminated cell lines threaten the development of treatment strategies for esophageal adenocarcinoma. J Natl Cancer Inst 102:271-274, 2010.
154. Grotenhuis BA, Wijnhoven BP, van Dekken H, van Lanschot JJ. Reply to the editor. J Thorac Cardiovasc Surg 139:1675, 2010.
155. Ramsoekh D, Haringsma J, Poley JW, van Putten P, van Dekken H, Steyerberg EW, van Leerdam ME, Kuipers EJ. A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut 59:785-793, 2010 .
156. Grotenhuis BA, Dinjens WNM, Wijnhoven BPL, Sonneveld P, Sacchetti A, Franken PF, van Dekken H, Tilanus HW, van Lanschot JJB, Fodde R. Barrett’s oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol 221:379-389, 2010.
157. De Vries AC, Haringsma J, de Vries RA, Ter Borg F, van Grieken NC, Meijer GA, van Dekken H, Kuipers EJ. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 15:259-264, 2010.
158. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71:1150-1158, 2010.
159. Leeuwenburgh I, Gerrits MM, Capello A, van den Bogert B, van Dekken H, Steyerberg EW, Siersema PD, Kuipers EJ. Expression of p53 as predictor for the development of esophageal cancer in achalasia patients. Dis Esophagus 23:506-11, 2010.
160. Van der Zee JA, Ten Hagen TL, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, van Eijck CH. Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer. Eur J Cancer 46:3393-3399, 2010.
161. Capelle LG, Haringsma J, de Vries AC, Steyerberg EW, Biermann K, van Dekken H, Kuipers EJ. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci 55:3442-3448, 2010.
162. Van de Winkel A, van Zoest KP, van Dekken H, Moons LM, Kuipers EJ, van der Laan LJ. Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. Histopathology 58:246-53, 2011.
163. Van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ. Fluorode-oxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253:56-63, 2011.
164. Gerrits MM, Chen M, Theeuwes M, van Dekken H, Sikkema M, Steyerberg EW, Lingsma HF, Siersema PD, Xia B, Kusters JG, van der Woude CJ, Kuipers EJ. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol (Dordr) 34:107-117, 2011.
165. Den Hoed CM, van Eijck BC, Capelle LG, van Dekken H, Biermann K, Siersema PD, Kuipers EJ. The prevalence of premalignant gastric lesions in asymptomatic patients: Predicting the future incidence of gastric cancer. Eur J Cancer 47:1211-1218, 2011.
166. Den Hoed CM, de Vries AC, Mensink PB, Dierikx CM, Suzuki H, Capelle L, van Dekken H, Ouwendijk R, Kuipers EJ. Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial. Can J Gastroenterol 25:207-213, 2011.
167. Van Putten PG, Hol L, van Dekken H, Han van Krieken J, van Ballegooijen M, Kuipers EJ, van Leerdam ME. Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. Histopathology 58:974-981, 2011.
168. Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, Borg FT, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, Ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 106:1231-1238, 2011.
169. Van de Winkel A, Menke V, Capello A, Moons LM, Pot RG, van Dekken H, Siersema PD, Kusters JG, van der Laan LJ, Kuipers EJ. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma. BMC Gastroenterol 11:108-117, 2011.
170. Van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, Ten Hagen TL. Angiogenesis: A prognostic determinant in pancreatic cancer? Eur J Cancer 47:2576-2584, 2011.
171. Menke V, Pot RG, Moons LM, van Zoest KP, Hansen B, van Dekken H, Siersema PD, Kusters JG, Kuipers EJ. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. J Hum Genet 57:26-32, 2012.
172. Lagerveld BW, van Dekken H, van Leenders G, van der Zee J. The role of pathology in small renal mass laparoscopic cryoablation. Adv Urol 2012:539648 (6 pages), 2012.
173. Overbeek LIH, Arkema JMS, Hofhuis EH, Rozendaal L, van Velthuysen MLF, van Dekken H, Nagtegaal ID. De mogelijkheden van het Pathologisch Landelijk Geautomatiseerd Archief. Ned Tijdschr Oncol 9:104-110, 2012.
174. Van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, Ten Hagen TL. Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. Eur J Surg Oncol 38:1058-1064, 2012.
175. Van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers GJ, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, for the CROSS-study Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012.
176. Cheng KH, Karres J, Kros JM, Kijlstra A, van Dekken H. Cyst-like schwannoma on the eyelid margin: an immunohistopathologic report. J Cran Surg 23:1215-1216, 2012.
177. Van der Zee JA, Ten Hagen TL, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, van Eijck CH. Bcl-2 associated anthanogen-1 (Bag-1) expression and prognostic value in pancreatic head and periampullary cancer. Eur J Cancer 49:323-328, 2013.
178. Talsma KA, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ; CROSS Study Group, Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 260:786-792, 2014.
179. Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Hulshof MC, van Berge Henegouwen MI, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg 260:807-813, 2014.
180. Selder JL, van Dekken H, de Voogt WG. The heart is not too noble to host a metastatic tumor! A right ventricle metastasis of a transitional cell carcinoma of the bladder. Neth Heart J 23:74-76, 2015.
181. Erdmann JI, Morak MJ, Duivenvoorden HJ, van Dekken H, Kazemier G, Kok NF, van Eijck CH. Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy. HPB (Oxford) 17:573-579, 2015.
182. Da Costa DW, van Dekken H, Witte BI, van Wagensveld BA, van Tets WF, Vrouenraets BC. Lymph Node Yield in Colon Cancer: Individuals Can Make the Difference. Dig Surg 32:269-274, 2015.
183. Da Costa DW, Vrouenraets BC, Witte BI, van Dekken H. Which Lymph Nodes Contain Metastases in Colon Cancer Patients? A Retrospective Histopathological Evaluation of 156 Patients. Int J Surg Pathol 23:623-628, 2015.
184. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GM, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090-1098, 2015.
185. Hagen PV, Heijl MV, Henegouwen MI, Boellaard R, Bossuyt PM, Kate FJ, van Dekken H, Hoekstra OS, Sloof GW, Lanschot JJ. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study. Dis Esophagus 30:1-7, 2017.